0001104659-24-067356.txt : 20240531
0001104659-24-067356.hdr.sgml : 20240531
20240531213600
ACCESSION NUMBER: 0001104659-24-067356
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240530
FILED AS OF DATE: 20240531
DATE AS OF CHANGE: 20240531
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kruse Bo
CENTRAL INDEX KEY: 0001752940
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38650
FILM NUMBER: 241011799
MAIL ADDRESS:
STREET 1: C/O Y-MABS THERAPEUTICS, INC.
STREET 2: 230 PARK AVENUE, 33RD FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10169
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Y-mAbs Therapeutics, Inc.
CENTRAL INDEX KEY: 0001722964
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 474619612
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 230 PARK AVENUE
STREET 2: SUITE 3350
CITY: NEW YORK
STATE: NY
ZIP: 10169
BUSINESS PHONE: 212-847-9841
MAIL ADDRESS:
STREET 1: 230 PARK AVENUE
STREET 2: SUITE 3350
CITY: NEW YORK
STATE: NY
ZIP: 10169
4
1
tm2416233-1_4seq1.xml
OWNERSHIP DOCUMENT
X0508
4
2024-05-30
0
0001722964
Y-mAbs Therapeutics, Inc.
YMAB
0001752940
Kruse Bo
C/O Y-MABS THERAPEUTICS, INC.
230 PARK AVENUE, SUITE 3350
NEW YORK
NY
10169
0
1
0
0
EVP, CFO, SECRY & TREAS.
0
Common Stock
2024-05-30
4
M
0
28629
2.00
A
239506
D
Common Stock
2024-05-30
4
S
0
28629
12.03
D
210877
D
Common Stock
2024-05-31
4
M
0
31371
2.00
A
242248
D
Common Stock
2024-05-31
4
S
0
31371
12.07
D
210877
D
Employee Stock Option (right to buy)
2.00
2024-05-30
4
M
0
28629
0
D
2025-06-10
Common Stock
28629
271371
D
Employee Stock Option (right to buy)
2.00
2024-05-31
4
M
0
31371
0
D
2025-06-10
Common Stock
31371
240000
D
This transaction was executed in multiple trades at prices ranging from $11.85 to $12.22, inclusive. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $11.87 to $12.42, inclusive. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
All of these stock options are currently vested.
/s/ John LaRocca, Attorney-in-Fact
2024-05-31